AFFiRiS GmbH
http://www.affiris.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AFFiRiS GmbH
Asia Deal Watch: Hanmi Licenses Greater China Rights To Dry AMD Injectable To AffaMed
Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.
Three OTC COVID-19 Tests Win FDA Clearance After Template Updates
Access Bio’s CareStart COVID-19 Antigen test gives results within 10 minutes, Becton, Dickinson’s BD Veritor within 15 minutes and InBios International’s SCoV-2 Ag Detect within 20 minutes. All three hold emergency use authorizations.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio
Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- AFFiRiS AG